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Abstract Duloxetine (Cymbalta) is a potent serotonin
norepinephrine reuptake inhibitor used for the management
of major depression and pain associated with diabetic
peripheral neuropathy. Cymbalta delayed-release capsules
contain Duloxetine HCl equivalent to 20, 30, 60 mg of
Duloxetine. The ingestion of high quantities of Duloxetine
may have serious outcomes such as venous thrombosis,
causing cardiac respiratory arrest. The Authors outline a
case report of an elderly woman, suffering from depression,
found dead in her apartment. The cause of death was
attributed to acute massive pulmonary thromboembolism
due to acute intoxication of Duloxetine bought the day
before. The thesis supported by the authors and confirmed
by the data from other studies is that a massive intake of
Duloxetine drug increases considerably the medication’s
side effects such as somnolence, dry mouth, fatigue,
insomnia, dizziness, constipation, considerable increases in
recumbent systolic and diastolic blood pressure, and a
small decrease in heart rate.
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Introduction
Duloxetine hydrochloride, sold under the brand names
Cymbalta, Ariclaim, Xeristar, Yentreve, is classified as an
antidepressant drug; it is a serotonin norepinephrine reup-
take inhibitor (SNRI). It was created by Lilly researchers1
and issued by the U.S. Food and Drugs Administration
(FDA) in August 2004 for treatment of major depressive
disorder (MDD) and in February 2007 for management of
generalized anxiety disorder.
In addition, Duloxetine and other antidepressants that
act via serotonergic or noradrenergic mechanisms have
analgesic properties. In September 2007, the FDA approved
Duloxetine for managing pain symptoms caused by periph-
eral neuropathy, diabetes [1], and fibromyalgia [2].
Duloxetine hydrochloride is a slightly brownish white
solid, which is somewhat soluble in water. Duloxetine is
available by delayed-release capsules containing enteric-
coated capsules of 22.4, 33.7, or 67.3 mg equivalent
to 20, 30, or 60 mg of Duloxetine hydrochloride, respec-
tively. These enteric-coated capsules are designed to pre-
vent the drug from degradation in the acidic stomach
environment.
The recommended dosage of Duloxetine is 40–60 mg/
day for depression, 60 mg/day for neuropathic pain, and
80 mg/day for stress urinary incontinence [3].
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1 David Robertson, David Wong, a co-discoverer of fluoxetine, and
Joseph Krushinski are listed as inventors on the patent application
filed in 1986 and granted in 1990. The first publication on the
discovery of the racemic form of duloxetine known as LY227942,
was made in 1988. The (?)-enantiomer of LY227942, assigned
LY248686, was chosen for further studies, because it inhibited
serotonin reuptake in rat synaptosomes two times more potently than
(–)-enantiomer. This molecule was subsequently named duloxetine.
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Duloxetine has an elimination half-life of about 12 h
(range 8–17 h), and its pharmacokinetics are dose-propor-
tional over the therapeutic range. Steady-state plasma
concentrations are typically achieved after 3 days of dos-
ing. When administered orally, a daily dose of Duloxetine
ranging between 30 and 129 mg shows the mean steady-
state serum concentration at 0.040 mg/l [5].
The dose is proportional to the plasma concentration,
which averages 0.95 ng/ml, ranging from 0.38 to 1.89 ng/
ml [6, 7]. Orally administered Duloxetine hydrochloride is
well absorbed. There is a median 2-h lag until absorption
begins, with maximal plasma concentrations of Duloxetine
occurring 6 h post-dose. Food does not affect the maximal
plasma concentration of Duloxetine, but delays the time to
reach peak concentration from 6 to 10 h, and it marginally
decreases absorption by about 10%. There is a 3-h delay in
absorption and a one-third increase in apparent clearance of
Duloxetine after an evening dose as compared with a
morning dose. The apparent volume of distribution aver-
ages about 1,640 l. Duloxetine is highly bound ([90%) to
proteins in human plasma, binding primarily to albumin
and a1-acid glycoprotein [7].
Elimination of Duloxetine involves hepatic metabolism
affecting two P450 isozymes, CYP1A2 and CYP2D6 [4].
The metabolites are primarily excreted into the urine in the
form of glucuronide and sulphate conjugates [4]. Duloxe-
tine comprises about 3% of the total radiolabeled material
in the plasma, indicating that it undergoes extensive
metabolism with numerous metabolites. The major bio-
transformation pathways for Duloxetine involve oxidation
of the naphthyl ring followed by conjugation and further
oxidation. Both CYP1A2 and CYP2D6 catalyse the oxi-
dation of the naphthyl ring in vitro. Metabolites found in
plasma include 4-hydroxy Duloxetine glucuronide and
5-hydroxy, 6-methoxy Duloxetine sulphate. Many addi-
tional metabolites have been identified in urine, some
representing only minor pathways of elimination. Only
trace (\1% of the dose) amounts of unchanged Duloxetine
are present in the urine. Most (about 70%) of the dose
appears in the urine as metabolites of Duloxetine; about
20% is excreted in the faces. Duloxetine undergoes
extensive metabolism, but the major circulating metabo-
lites have not been shown to contribute significantly to
pharmacologic activity of Duloxetine [7].
The literature reports the following common side effects
associated with an Duloxetine overdose: nausea, headache,
dry mouth, fatigue, insomnia, dizziness, somnolence,
constipation, considerable increases in recumbent systolic
and diastolic blood pressure, and a small decrease in heart
rate [6, 7].
A review of the annual reports of the American Asso-
ciation of Poison Control Centers (AAPCC) shows that
there has been an increase in fatal cases in which
Duloxetine has been identified: 5 cases in 2005 [8], 11
cases in 2006 [9], 14 cases in 2007 [10], 18 cases in 2008
[11], 23 cases in 2009 [12]. Unfortunately, postmortem
blood levels were documented in association with only four
of those cases.
Most of the poisonings are caused by ‘cocktail’ drugs; in
a few cases the intoxications are due to only Duloxetine
abuse that caused pulmonary embolism [13].
There is a paucity of published data regarding the
potential postmortem threshold blood levels for Duloxetine
toxicity and lethality; the only published study found was
recently conducted by the Los Angles County Coroner’s
Office and the Lehigh Valley Medical Center [13].
These researchers hope to conduct further studies
about the postmortem Duloxetine levels in blood and par-
ticularly research into fatal cases where only Duloxetine is
involved [13].
Case Report
In June 2010, paramedics were called by the victim’s
acquaintance to the apartment of a 75-years-old white
woman who was unresponsive.
The woman suffered major depression for approxi-
mately 1 year caused by the death of her son; she was
undergoing treatment with a psychiatrist who prescribed
psychotropic drugs. The woman was found lying supine on
the bed next to a hand-written suicide note.
Antidepressant drugs found in the rubbish bin in the
kitchen included:
• 1 Rivotril bottle, oral drops (clonazepam 25 mg/ml)
• 1 Cymbalta2 blister containing 4 capsules (Duloxetine
60 mg), bought the day before (1 Cymbalta blister
2 The efficacy of Cymbalta as a treatment for depression was
established in 4 randomized, double-blind, placebo-controlled, fixed-
dose studies in adult outpatients (18–83 years), meeting DSMIV
criteria for major depression. In 2 studies, patients were randomized
to Cymbalta 60 mg once daily (N = 123 and N = 128, respectively)
or placebo (N = 122 and N = 139, respectively) for 9 weeks; in the
third study, patients were randomized to Cymbalta 20 or 40 mg twice
daily (N = 89) for 8 weeks; in the fourth study, patients were
randomized to Cymbalta 40 or 60 mg twice daily (N = 95 and
N = 93, respectively) or placebo (N = 93) for 8 weeks. There is not
evidence that doses greater than 60 mg/day confer additional benefits.
In all 4 studies, Cymbalta demonstrated superiority over placebo as
measured by improvement in the 17-item Hamilton Depression
Rating Scale (HAMD17) total score. In all of these clinical studies,
analyses of the relationship between treatment outcome and age,
gender, and race did not suggest any differential responsiveness on
the basis of these patient characteristics. In another study, 533 patients
meeting DSMIV criteria for MDD received Cymbalta 60 mg once
daily during an initial 12-week open-label treatment phase. Two
hundred and seventy-eight patients who responded to open-label
treatment (defined as meeting the following criteria at weeks 10 and
12: a HAMD17 total score B9, Clinical Global Impressions of
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contains 28 capsules, meaning the woman ingested 24
capsules)
• 1 empty Triptich bottle (trazodone 25 mg/ml)
• 1 Mirtazepine blister containing 1 capsule (30 mg/
capsule)
The doctor on the scene pronounced the cause of death
as cardiac respiratory arrest possibly as a result of an
overdose of her prescribed medication.
The postmortem examination was performed 1 day after
death, and the cause of death was attributed to acute
massive pulmonary thromboembolism due to acute intox-
ication by Duloxetine. Nothing in the patient’s history was
suggestive of a genetic predisposition to pulmonary
embolism.
Furthermore, the patient was not alcoholic, and this is
important because the alcoholism potentiates the Duloxe-
tine toxicity.
Systematic chemical–toxicological analyses were per-
formed on the blood, urine, bile, liver, and brain samples to
investigate the presence of drug overdose found in the
apartment that could justify the cardiac respiratory arrest
death.
A peripheral blood sample was collected in a vial con-
taining sodium fluoride. All other autopsy specimens were
stored without preservative.
Solid tissues were homogenized within their own fluid
or at 1:1 dilution (w/v) with distilled water. All biological
specimens were refrigerated at 4C.
Postmortem specimens were submitted for toxicology
testing.
The presence of alcohol and toxic volatile or gaseous
molecules in the peripheral blood samples were performed
by headspace GCFID (flame ionization detection): there
was no presence of alcohol in the blood; urine samples
were screened by enzyme immunoassay (EMIT) to find
traces of drug abuse from amphetamines and/or deriva-
tives, methadone, cannabinoids, barbiturates, cocaine,
opiates.
Quantification of basic drug levels in the organs and
biological fluids was performed by GCMS (GC mass
spectrophotometry) following liquid–liquid back extrac-
tion. Basic drugs were initially qualitatively detected on
routine drug screening using GCNPD (gas chromatography
with nitrogen–phosphorous detection) and GCMS. With
positive screening, quantisation was undertaken using
GCMS with a detection limit of 30 ng/ml.
Mirtazapine, Citalopram, and Duloxetine were identified
in a basic drug screen. The presence of benzodiazepines
molecules has not found in significant amounts.
The drug distribution into the tissues is summarized in
Table 1.
Discussion
Positive chemical–toxicological analyses conducted on
biological samples of the deceased identified some of the
drugs found in the apartment. The following antidepressant
substances were detected in the organs and biological flu-
ids: Mirtazapine, Citalopram, and Duloxetine.
Mirtazapine was detected in the blood at a concentration
of 31 ng/ml; this concurs with the literature review as
appropriate in subjects who have taken the drug in thera-
peutic doses [7, 14, 15].
The same considerations must be made regarding the
hematic concentration of Citalopram found in the blood
measuring (59 ng/ml). This concentration is also in
accordance with the literature data, which indicates that an
intake of a single drug tablet contains a concentration of
Citalopram ranging from 42 to 52 ng/ml [7, 14, 15].
In continued consumption, Citalopram presents an
average level in blood concentration of 79 ng/ml [16–18].
The data concerning to Duloxetina concentration in the
patient’s blood, showed a supra-therapeutic intake of this
drug (1,209 ng/ml). The cause of death proclaimed by the
coroner was due to acute intoxication by Duloxetine; he
stated, ‘It is more likely than not that she took too much of
her antidepressant medication Duloxetine…’.
The literature shows the concentrations measured, which
would mean the ingestion of the active principle rang-
ing from 1,322 to 1,440 ng/ml (22–24 tablets of drug)
[5, 19, 20].
In their studies, Anderson et al. [13] claim that the
postmortem blood concentrations associated with the con-
sumption of therapeutic doses of Duloxetine (60 mg/daily)
are between 0.02 and 0.11 ng/ml. Only in case of
Table 1 Postmortem tissues distribution (ng/ml)
Mirtazapine Citalopram Duloxetine
Liver 225 555 14,196
Brain 54 63 1,931
Femoral blood 31 59 1,209
Urine 960 559 1,496
Bile 2,246 345 16,385
Footnote 2 continued
Severity B2, and not meeting the DSMIV criteria for MDD) were
randomly assigned to continuation of Cymbalta at the same dose
(N = 136) or to placebo (N = 142) for 6 months. Patients on
Cymbalta experienced a statistically significant longer time to relapse
of depression than did patients on placebo. Relapse was defined as an
increase in yhe CGIS score of C2 points compared with that obtained
at week 12, as well as meeting the DSMIV criteria for MDD at 2
consecutive visits at least 2 weeks apart, where the 2-week temporal
criterion had to be satisfied at only the second visit.
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descriptions of lethal intoxication by Duloxetine, post-
mortem blood concentrations measured between ND (not
detected) and 0.59 ng/ml (N = 12); 9 out of 12 cases
showed major postmortem blood concentrations than the
normal therapeutic levels mentioned before.
In the case report, the supra-therapeutic doses confirmed
by the massive blood concentrations observed could justify
that somnolence, a reported side effect of Duloxetine,
culminated a stupor that made the woman unconscious and
unresponsive for an extended period. It should also be
noted that the effect of drowsiness leading to immobiliza-
tion is amplified in patients with more than 60 years who
have already slowed motor movements. The patient was
75 years old and slowed motor movements due to age, so
the immobilization due to Duloxetine was amplified con-
sidering the huge quantitative swallowed.
This situation produced, pronounced by the coroner, an
acute massive pulmonary thromboembolism and may have
been the cause of death. Forensic analysis of the woman’s
body indicated that the pulmonary thromboembolism
occurred about 8 h after the onset of immobility. Pre-
marketing Cymbalta clinical studies looking into MDD,
using a sample population of subjects aged 65 years and
above, showed that usage is associated with cases of clin-
ically significant hyponatremia, leading to possible extreme
consequences such as lethargy, decreased consciousness,
and venous thrombosis [5, 7, 16].
The cause of venous thromboembolism is multifactorial,
and several hypotheses have been proposed explaining the
association between venous thromboembolism and psy-
chotropic drugs. The use of these drugs might predispose to
the possibility of venous thrombosis because of side effects
such as sedation and immobilisation [21–23]. Specifically,
three factors favour venous thrombogenesis: damage to the
vessel wall; stasis or slowing blood flow; and abnormalities
of coagulation, all of which are identified as possible side
effects from Duloxetine [21–23].
Several studies of Duloxetine [24–26] suggest that at
levels [700 ng/ml, this antidepressant drug may poten-
tially contribute to the lethal pharmacodynamic substrate
and precipitate a fatal outcome.
A significant study conducted by Rosendal [27] and
Motykie [28] examines the cause of death on subjects at
18- and 65-years-old who use antidepressants like Dul-
oxetine compared with subjects of the same age range who
are nonusers of antidepressants. The study proved a strong
correlation between users of Duloxetine and death from
pulmonary embolism [27]. The researches conducted by
Eli Lilly on elderly patients in order to market the
Cymbalta show that comparing the users of antidepressants
with nonusers, the risk of pulmonary embolism increases in
proportion to age among those who use antidepressants,
reaching a peak in the age range between 58- and 65-years-
old [3].
The association between pulmonary embolism and
antidepressant use is further supported by a higher pro-
portion of venous thromboembolism among young users
compared with young nonusers of antidepressants [27].
The statements made in the literature review and the
toxicological results obtained affirm that the sedative effect
of Duloxetine contributed to venous stasis, which caused a
pulmonary thromboembolism in the patient [3, 6, 9].
However, the biological mechanism explaining the
relationship between Duloxetine and venous thrombosis is
unknown; further investigations are necessary to gain a
better understanding of the drug and its potential role in
causing deaths.
Conclusions
Duloxetine is a relatively new antidepressant medication.
This report provides case details where Duloxetine was
found at a supra-therapeutic concentration, indicating the
possibility that a greater dose than prescribed was taken.
The toxicological results, the Coroner’s statement, the data
obtained, and the literature review all confirm that venous
thrombosis would appear to be associated with the use of
antidepressant drugs like Duloxetine, in psychiatric
patients. More specifically, the thesis supported by the
authors would appear to be corroborated: a massive intake
of Duloxetine drug can increase considerably the medica-
tion’s side effects of sedation and immobilisation causing a
venous thrombosis. Considering possible increases in the
prevalence of Duloxetine prescriptions, further investiga-
tions are required to gain a better understanding of the
postmortem behaviour of this drug and its potential role in
causing death.
The authors, aware that important information pertinent
to the development of thromboembolism is not known in
this patient, believe that the value of this article is not so
much in proving any causal link between thromboembo-
lism and Cymbalta (Duloxetine), but in reinforcing the
need for awareness of the possibility of thromboembolism
complicating overdose with Duloxetine.
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